Insys Therapeutics(INSY) Short, by Mr.

Tietzsche

Summary of this report:

The "Breakthrough" Cancer pain medication is shrinking revenue for
last two years
Still waiting(over a year) on that phase III oral solution Epilepsy study
to start.
Buprenorphine sublingual spray phase III Insys said they completing
was actually Terminated.
2017 has already started out terrible for them, But it's okay because
the NDA submission of the terminated study is going to happen the
2nd Half of 2017
Key points
1. Their one product on the market is shrinking in
revenue
2. Their saving grace for 2017-2019 is based on a

LIE.
Reading this report, you agree that use of Friedrich Tietzsche research is at your own risk. In no
event will you hold Friedrich Tietzsche or any affiliated party liable for any direct or indirect
trading losses caused by any information in this report. This report is not investment advice or a
recommendation or solicitation to buy or sell any securities.You agree to do your own research
and due diligence before making any investment decision with respect to securities covered
herein. You represent to Friedrich Tietzsche that you have sufficient investment sophistication to
critically assess the information, analysis and opinions in this report.You further agree that you
will not communicate the contents of this report to any other person unless that person has
agreed to be bound by these same terms of service.Conflict of Interest Advice: You should
assume that on the publication date of this report, Friedrich Tietzsche has a net short position
with respect to the shares (and/or options, swaps, and other derivatives related to the shares) of
the issuer discussed in this report. Therefore, Friedrich Tietzsche
stands to profit in the event the issuers share price declines, and may incur investment losses if
such issuers share price increases, following the date of this report. This report, therefore,
specifically emphasizes negative aspects of the issuer that Friedrich Tietzsche believes have
not been properly reflected in the share price of the issuer. Friedrich Tietzsche may buy, sell,
cover or otherwise change the form or substance of its position in the issuer in its sole discretion
at any time. Friedrich Tietzsche disclaims any obligation to notify the market of any such
changes in advance.This research and report includes forward-looking statements, estimates,
projections,assessments, beliefs, views, and opinions of Friedrich Tietzsche prepared with
respect to, among other things, certain accounting, legal, and regulatory issues the issuer may
faces and the potential impact of those issues on its future business, financial condition and
results of operations, as well as more generally, t
he issuers anticipated operating performance, access to capital markets,
market conditions, assets and liabilities. Such statements, estimates, projections and opinions
may prove to be substantially inaccurate and are inherently subject to significant risks and
uncertainties beyond Friedrich Tietzsche control.This research and report expresses Friedrich
Tietzsche opinions, which have been solely based upon publicly available information, as well
as inferences and deductions through our research and analytical process. Friedrich Tietzsche
believes all factual information contained herein to be accurate and reliable, and has obtained
such information from public sources believed to be accurate and reliable. However, the issuer
may possess or have access to information that materially differs from the information presented
herein.
- Legal warring taken from Art Doyle
The Recent CEO's of the Company:

Michael Babich ARRESTED AND

STEPPED down from CEO.

John Kapoor was also arrested in the

same incident, after became the CEO. Seems like a smart guys...

And as the saying goes, if the ship is sinking get the fuck out. John Kapoor stepped
down from CEO and his chairman positions. And put Santosh Vetticaden, who then in
three month also left and put Saeed Motahari.

This company goes through a lot of CEO's

 The Buprenorphine sublingual spray

Completed?

Even if this drug is complete it is the "Same shit

different air freshener."
of the Fentanyl Sublingual Spray or SUBSYS which
is the current drug they have on the market. The
Demand for the SUBSYS was so low, and
competition so high they were arrested for bribing
doctors to inscribe it to unneeding patients.

Although they do own the IP for the sprays they are

doomed like the revenue from SUBSYS and the
possible revenue from Buprenorphine.